I particularly like this bit....
“The CLTX CAR T dose escalation preliminary data are truly encouraging and have exceeded our
expectations, particularly given that the patients enrolled were heavily pretreated and very late
stage,” said Jennifer Chow, CEO and Managing Director of Chimeric Therapeutics.
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(10.0%) |
Mkt cap ! $9.068M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $2.056K | 411.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 47 | 26967650 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5217011 | 2 |
View Market Depth
| Last trade - 15.39pm 22/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |